Latest news and press releases about REGENXBIO Inc. (RGNX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Price
| Price | $7.98 |
| Market Cap | $413M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.87 |
| EV / EBITDA | -3.56 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -220.07% |
| Return on Invested Capital | -52.72% |
| Return on Assets | -50.81% |
| Gross Margin | 54.22% |
| Operating Margin | -94.08% |
| Net Margin | -112.58% |
Related companies: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explore sector: Healthcare · Biotechnology
More sections of RGNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks